Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

878 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00548-8. doi: 10.1016/S0140-6736(24)00548-8. Online ahead of print. Lancet. 2024. PMID: 38763154 Free article.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00549-X. doi: 10.1016/S0140-6736(24)00549-X. Online ahead of print. Lancet. 2024. PMID: 38763153 Free article.
Impact of a varied set of stimuli on a suite of immunological parameters within peripheral blood mononuclear cells: toward a non-animal approach for assessing immune modulation by materials intended for human use.
Cochrane S, Rajagopal R, Sheffield D, Stewart F, Hathaway L, Barnes NM, Qureshi O, Gordon J. Cochrane S, et al. Among authors: barnes nm. Front Toxicol. 2024 Apr 26;6:1335110. doi: 10.3389/ftox.2024.1335110. eCollection 2024. Front Toxicol. 2024. PMID: 38737195 Free PMC article.
A multi-centre investigation of macrovascular and non-ocular microvascular complications in children and adolescents with diabetes mellitus in southern Ghana.
Akpalu J, Essuman VA, Amoaku WM, Abaidoo B, Essuman A, Hayfron-Benjamin C, Barnes NA, Tagoe NN, Asare G, Ndanu TA, Appiah-Thompson B, Ofori-Adjei ID, Sackey AH. Akpalu J, et al. Among authors: barnes na. Ghana Med J. 2023 Jun;57(2):87-96. doi: 10.4314/gmj.v57i2.2. Ghana Med J. 2023. PMID: 38504754 Free PMC article.
Relaxation of mitochondrial hyperfusion in the diabetic retina via N6-furfuryladenosine confers neuroprotection regardless of glycaemic status.
Anderson A, Alfahad N, Wimalachandra D, Bouzinab K, Rudzinska P, Wood H, Fazey I, Xu H, Lyons TJ, Barnes NM, Narendran P, Lord JM, Rauz S, Ganley IG, Curtis TM, Wallace GR, Hombrebueno JR. Anderson A, et al. Among authors: barnes nm. Nat Commun. 2024 Feb 6;15(1):1124. doi: 10.1038/s41467-024-45387-9. Nat Commun. 2024. PMID: 38321058 Free PMC article.
Facilitating self-care through community pharmacy in England.
Rutter P, Barnes N. Rutter P, et al. Among authors: barnes n. Explor Res Clin Soc Pharm. 2023 Dec 28;13:100404. doi: 10.1016/j.rcsop.2023.100404. eCollection 2024 Mar. Explor Res Clin Soc Pharm. 2023. PMID: 38292864 Free PMC article.
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro.
Qureshi OS, Sutton EJ, Bithell RF, West SM, Cutler RM, McCluskey G, Craggs G, Maroof A, Barnes NM, Humphreys DP, Rapecki S, Smith BJ, Shock A. Qureshi OS, et al. Among authors: barnes nm. MAbs. 2024 Jan-Dec;16(1):2300155. doi: 10.1080/19420862.2023.2300155. Epub 2024 Jan 19. MAbs. 2024. PMID: 38241085 Free PMC article.
878 results